MASH (formerly NASH)
Inflammatory fatty liver disease tied to obesity. GLP-1s show histologic benefit.
Metabolic dysfunction-associated steatohepatitis is the inflammatory form of fatty liver disease, renamed from NASH in 2023. Weight loss is the most evidence-supported intervention, and GLP-1s show histologic improvement in trials.